Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Company Information
About this company
Key people
Helge Lubenow
Chairwoman of the Supervisory Board
Alexander Link
Deputy Chairman of the Supervisory Board
Hansjoerg Plaggemars
Member of the Management Board
Jochen Hummel
Member of the Supervisory Board
Click to see more
Key facts
- Shares in issue876,949.00
- EPICECX
- ISINDE000A37FT41
- LocationGermany
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap€789,250.00
- Employees3
- ExchangeFrankfurt Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.